PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide:: First results in patients with meningiomas

被引:0
|
作者
Henze, M
Schuhmacher, J
Hipp, P
Kowalski, J
Becker, DW
Doll, J
Mäcke, HR
Hofmann, M
Debus, J
Haberkorn, U
机构
[1] Univ Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, D-6900 Heidelberg, Germany
[3] Univ Basel Hosp, CH-4031 Basel, Switzerland
[4] Hannover Med Sch, D-3000 Hannover, Germany
关键词
somatostatin receptors; DOTATOC; Ga-68; PET; meningioma;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Imaging of somatostatin receptors (SSTRs) using [In-111]diethylenetriaminepentaacetic-acid-octreotide (DTPAOC) has proven to be helpful in the differentiation of meningiomas, neurinomas or neurofibromas, and metastases as well as in the follow-up of meningiomas, A drawback of the SPECT method is its limited sensitivity in detecting small meningiomas. Because of PET's increased spatial resolution and its ability to absolutely quantify biodistribution, a PET tracer for SSTR imaging would be desirable. Methods: 1,4,7,10-tetraazacyclododecane-N,N ' ,N "N ' ' ' -tetraacetic-acid-D-Phe(1)-Tyr(3)-octreotide (DOTATOC) was labeled using the positron-emitting generator nuclide Ga-68. We acquired dynamic PET images over 120 min after intravenous injection of 175 MBq [Ga-68]DOTATOC in 3 patients suffering from 8 meningiomas (WHO I-o; 7- to 25-mm diameter). Patients' heads had been fixed using individually shaped fiber masks equipped with an external stereotactic localizer system to match PET, CT, and MRI datasets. Results: [68Ga]DOTATOC was rapidly cleared from the blood (half-life alpha, 3.5 min; half-life beta, 63 min). Standardized uptake values (SUVs) of meningiomas increased immediately after injection and reached a plateau 60-120 min after injection (mean SUV, 10.6). No tracer could be found in the surrounding healthy brain tissue. AH meningiomas (even the 3 smallest [7- to 8-mm diameter]) showed high tracer uptake and could be visualized clearly. Tracer boundaries showed a good correspondence with the matched CT and MRI images. PET provided valuable additional information regarding the extent of meningiomas located beneath osseous structures, especially at the base of the skull. Conclusion: According to our initial experiences, [Ga-68]DOTATOC seems to be a very promising new PET tracer for imaging SSTRs even in small meningiomas, offering excellent imaging properties and a very high tumor-to-background ratio.
引用
收藏
页码:1053 / 1056
页数:4
相关论文
共 50 条
  • [41] First experiences with the SST2R-antagonist [68Ga]Ga-DATA5m-LM4 for PET imaging of tumors: preclinical comparison with [68Ga] Ga-DOTA-LM3
    Kanellopoulos, Panagiotis
    Nock, Berthold A.
    Baum, Richard
    Roesch, Frank
    Maina-Nock, Theodosia
    NUCLEAR MEDICINE AND BIOLOGY, 2022, 114 : S16 - S17
  • [42] Detection of Bone Metastases in Patients with Neuroendocrine Tumors using 68Ga-DOTA-Tyr3-Octreotide PET in comparison to CT and 18F-NaF PET bone scintigraphy
    Putzer, D.
    Kendler, D.
    Henninger, B.
    Uprimny, C.
    Gabriel, M.
    Kovacs, P.
    Dobrozemsky, G.
    Decristoforo, C.
    Virgolini, I. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S132 - S132
  • [43] Detection of somatostatin receptor-positive tumours using the new99mTc-tricine-HYNIC-D-Phe1-Tyr3-octr eotide: First results in patients and comparison with111ln-DTPA-D-Phe1-octreotide
    Bangard, M.
    Béhé, M.
    Guhlke, S.
    Otte, R.
    Bender, H.
    Maecke, H.R.
    Biersack, H.J.
    2000, Springer Verlag (27) : 628 - 637
  • [44] [18F]AlF-NOTA-octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue imaging in neuroendocrine tumour patients: results of planned interim analysis of a prospective registration trial
    Pauwels, E.
    Cleeren, F.
    Tshibangu, T.
    Koole, M.
    Serdons, K.
    Boeckxstaens, L.
    Dekervel, J.
    Van Cutsem, E.
    Verslype, C.
    Stroobants, S.
    Vandamme, T.
    Lybaert, W.
    Geboes, K.
    Bormans, G.
    Deroose, C. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S138 - S139
  • [45] Impact on clinical management when using [18F]AlFNOTA-octreotide instead of [68Ga]Ga-DOTA-SSA PET/CT in neuroendocrine tumor patients: preliminary results
    Leupe, H.
    Pauwels, E.
    Vandamme, T.
    Van den Broeck, B.
    Lybaert, W.
    Dekervel, J.
    Jaekers, J.
    Cleeren, F.
    Hofland, J.
    Brouwers, A.
    Koole, M.
    Bormans, G.
    Van Cutsem, E.
    Geboes, K.
    Verslype, C.
    Stroobants, S.
    Deroose, C. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S508 - S508
  • [46] Failure of functional imaging with gallium-68-DOTA-D-Phe1-Tyr3-octreotide positron emission tomography to localize the site of ectopic adrenocorticotropic hormone secretion: A case report
    Gani L.U.
    Gianatti E.J.
    Cheung A.S.
    Jerums G.
    MacIsaac R.J.
    Journal of Medical Case Reports, 5 (1)
  • [47] Comparison of target volume definition for radiation therapy based on contrast-enhanced MRI, O-(2-(18F)-fluoroethyl)-L-tyrosine (FET)- and (68 Ga)-DOTA-D Phe 1-3Tyr3-Octreotide (DOTATOC)-PET in patients with meningiomas
    Dittmar, J. O.
    Giesel, F.
    Kratochwill, K.
    Christmann, A.
    Welzel, T.
    Habermehl, D.
    Rieken, S.
    Haberkorn, U.
    Debus, J.
    Combs, S. E.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 39 - 40
  • [48] Comparison of somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide and chromogranin A assay results in patients with neuroendocrine tumours
    Rodrigues, M.
    Heute, D.
    Gabriel, M.
    Putzer, D.
    Griesmacher, A.
    Virgolini, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S175 - S175
  • [49] Comparative study of In-111-DOTA-Lanreotide (LAN), In-111-DTPA-D-Phe-1-Octreotide (OCT), In-111-DOTA-Tyr-3-Octreotide (TOCT) and F-18-FDG-PET in neuroendocrine tumor patients
    Virgolini, I
    Kurtaran, A
    Smith-Jones, P
    Havlik, E
    Traub, T
    Leimer, M
    Ofluoglu, S
    Andreae, F
    Raderer, M
    Angelberger, P
    Becherer, A
    Niederle, B
    Kletter, K
    Schima, W
    Dudczak, R
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1156 - 1156
  • [50] [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
    Elin Pauwels
    Frederik Cleeren
    Térence Tshibangu
    Michel Koole
    Kim Serdons
    Jeroen Dekervel
    Eric Van Cutsem
    Chris Verslype
    Koen Van Laere
    Guy Bormans
    Christophe M. Deroose
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 3033 - 3046